Neurodevelopmental Outcomes of Extremely Preterm Infants Randomized to Stress Dose Hydrocortisone

Objective To compare the effects of stress dose hydrocortisone therapy with placebo on survival without neurodevelopmental impairments in high-risk preterm infants. Study Design We recruited 64 extremely low birth weight (birth weight ≤1000g) infants between the ages of 10 and 21 postnatal days who were ventilator-dependent and at high-risk for bronchopulmonary dysplasia. Infants were randomized to a tapering 7-day course of stress dose hydrocortisone or saline placebo. The primary outcome at follow-up was a composite of death, cognitive or language delay, cerebral palsy, severe hearing loss, or bilateral blindness at a corrected age of 18–22 months. Secondary outcomes included continued use of respiratory therapies and somatic growth. Results Fifty-seven infants had adequate data for the primary outcome. Of the 28 infants randomized to hydrocortisone, 19 (68%) died or survived with impairment compared with 22 of the 29 infants (76%) assigned to placebo (relative risk: 0.83; 95% CI, 0.61 to 1.14). The rates of death for those in the hydrocortisone and placebo groups were 31% and 41%, respectively (P = 0.42). Randomization to hydrocortisone also did not significantly affect the frequency of supplemental oxygen use, positive airway pressure support, or need for respiratory medications. Conclusions In high-risk extremely low birth weight infants, stress dose hydrocortisone therapy after 10 days of age had no statistically significant effect on the incidence of death or neurodevelopmental impairment at 18–22 months. These results may inform the design and conduct of future clinical trials. Trial Registration ClinicalTrials.gov NCT00167544

[1]  M. Greene,et al.  Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years , 2014, Journal of Perinatology.

[2]  L. Doyle,et al.  Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2014, The Cochrane database of systematic reviews.

[3]  M. Laughon,et al.  Medication Use in the Neonatal Intensive Care Unit , 2013, American Journal of Perinatology.

[4]  Ponnada A. Narayana,et al.  Perinatal Clinical Antecedents of White Matter Microstructural Abnormalities on Diffusion Tensor Imaging in Extremely Preterm Infants , 2013, PloS one.

[5]  J. Tyson,et al.  Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. , 2013, The Journal of pediatrics.

[6]  Bethany J Figg,et al.  National Institute of Child Health and Human Development , 2013 .

[7]  A. Jefferies Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. , 2012, Paediatrics & child health.

[8]  Nancy Bayley,et al.  BAYLEY SCALES OF INFANT AND TODDLER DEVELOPMENT, THIRD EDITION (BAYLEY-III) , 2014 .

[9]  Charles R. Bauer,et al.  Are outcomes of extremely preterm infants improving? Impact of Bayley assessment on outcomes. , 2012, The Journal of pediatrics.

[10]  M. Walsh,et al.  Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. , 2011, American journal of respiratory and critical care medicine.

[11]  Riitta Parkkola,et al.  Associations between regional brain volumes at term-equivalent age and development at 2 years of age in preterm children , 2011, Pediatric Radiology.

[12]  Daniel Rueckert,et al.  An optimised tract-based spatial statistics protocol for neonates: Applications to prematurity and chronic lung disease , 2010, NeuroImage.

[13]  K. Watterberg Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia , 2010, Pediatrics.

[14]  I. Seri,et al.  Hydrocortisone for hypotension and vasopressor dependence in preterm neonates: A meta-analysis , 2010, Journal of Perinatology.

[15]  L. Doyle,et al.  Postnatal Hydrocortisone for Preventing or Treating Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review , 2010, Neonatology.

[16]  Jessica Dubois,et al.  Brain Development of the Preterm Neonate after Neonatal Hydrocortisone Treatment for Chronic Lung Disease Patients and Methods , 2022 .

[17]  D. Hirtz,et al.  The ELGAN study of the brain and related disorders in extremely low gestational age newborns. , 2009, Early human development.

[18]  B. Yoder,et al.  Time-Related Changes in Steroid Use and Bronchopulmonary Dysplasia in Preterm Infants , 2009, Pediatrics.

[19]  B. Vohr,et al.  Stability of Neuromotor Outcomes at 18 and 30 Months of Age After Extremely Low Birth Weight Status , 2009, Pediatrics.

[20]  Nehal A Parikh,et al.  Intensive care for extreme prematurity--moving beyond gestational age. , 2008, The New England journal of medicine.

[21]  K. Watterberg,et al.  Growth and Neurodevelopmental Outcomes After Early Low-Dose Hydrocortisone Treatment in Extremely Low Birth Weight Infants , 2007, Pediatrics.

[22]  D. Grobbee,et al.  Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. , 2007, The Journal of pediatrics.

[23]  Nehal A Parikh,et al.  Postnatal Dexamethasone Therapy and Cerebral Tissue Volumes in Extremely Low Birth Weight Infants , 2007, Pediatrics.

[24]  P. Kamphuis,et al.  Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? , 2007 .

[25]  Mark Schluchter,et al.  Poor Predictive Validity of the Bayley Scales of Infant Development for Cognitive Function of Extremely Low Birth Weight Children at School Age , 2005, Pediatrics.

[26]  F. Lazeyras,et al.  Structural and Functional Brain Development After Hydrocortisone Treatment for Neonatal Chronic Lung Disease , 2005, Pediatrics.

[27]  R. Lasky,et al.  The effects of early lead exposure on the brains of adult rhesus monkeys: a volumetric MRI study. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  M. Hallman,et al.  Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. , 2005, The Journal of pediatrics.

[29]  L. Doyle,et al.  Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease , 2005, Pediatrics.

[30]  L. Stokowski THE NEONATAL RESEARCH NETWORK , 2004 .

[31]  A. Leviton,et al.  Lung and Brain Damage in Preterm Newborns , 2004, Neonatology.

[32]  T. Yeh,et al.  Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. , 2004, The New England journal of medicine.

[33]  Richard A. Jones,et al.  MRI of the neonatal brain: optimization of spin-echo parameters. , 2004, AJR. American journal of roentgenology.

[34]  Joseph V Hajnal,et al.  T2 relaxation values in the developing preterm brain. , 2003, AJNR. American journal of neuroradiology.

[35]  F. Bel,et al.  Short‐ and long‐term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? , 2003, Acta paediatrica.

[36]  David J Larkman,et al.  Diffusion-weighted imaging of the brain in preterm infants with focal and diffuse white matter abnormality. , 2003, Pediatrics.

[37]  A. Anderson,et al.  Regional brain volumes and their later neurodevelopmental correlates in term and preterm infants. , 2003, Pediatrics.

[38]  R. Ehrenkranz,et al.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[39]  R. Ehrenkranz,et al.  Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[40]  R. Ehrenkranz,et al.  Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[41]  J. Perlman Concern about Fetus and Newborn Committee statement on corticosteroid use. , 2002, Pediatrics.

[42]  H. Jacobs,et al.  Premature conclusions on postnatal steroid effects. , 2002, Pediatrics.

[43]  P. Shah,et al.  Meta-analysis of postnatal steroid use challenged. , 2002, Pediatrics.

[44]  C. McEvoy,et al.  A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. , 2002, Pediatrics.

[45]  K. Kennedy Controversies in the use of postnatal steroids. , 2001, Seminars in perinatology.

[46]  A. Sandler Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease , 2001 .

[47]  W Tin,et al.  Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation , 2001, Archives of disease in childhood. Fetal and neonatal edition.

[48]  K. Barrington The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs , 2001, BMC pediatrics.

[49]  H. Halliday Postnatal steroids: A dilemma for the neonatologist , 2001, Acta paediatrica.

[50]  F. Cowan,et al.  Reduced development of cerebral cortex in extremely preterm infants , 2000, The Lancet.

[51]  B. Vohr,et al.  Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. , 2000, Pediatrics.

[52]  J. Flynn,et al.  Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. , 2000, Pediatrics.

[53]  M. G,et al.  Randomized trial of Permissive hypercapnia in preterm infants , 2000 .

[54]  A. Jobe The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.

[55]  M A Rutherford,et al.  Magnetic resonance imaging of the brain in a cohort of extremely preterm infants. , 1999, The Journal of pediatrics.

[56]  T. Yeh,et al.  Early Dexamethasone Therapy and Blood Cell Count in Preterm Infants , 1999, Pediatrics.

[57]  D. Birnkrant,et al.  Effect of Dexamethasone on Lymphocyte Subpopulations in Premature Infants with Bronchopulmonary Dysplasia , 1999, Journal of Perinatology.

[58]  B. Yoder,et al.  Early prediction of neonatal chronic lung disease: A comparison of three scoring methods , 1999, Pediatric pulmonology.

[59]  J. Tyson,et al.  A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. , 1998, The New England journal of medicine.

[60]  R. Kikinis,et al.  Quantitative magnetic resonance imaging of brain development in premature and mature newborns , 1998, Annals of neurology.

[61]  W. Covitz,et al.  Cardiac effects of dexamethasone in very low birth weight infants. , 1996, Pediatrics.

[62]  G. Greisen [Chronic lung disease in premature infants]. , 1995, Ugeskrift for laeger.

[63]  P. Groneck,et al.  Inflammatory mediators and bronchopulmonary dysplasia. , 1995, Archives of disease in childhood. Fetal and neonatal edition.

[64]  J. Pinto-Martin,et al.  Cranial ultrasound prediction of disabling and nondisabling cerebral palsy at age two in a low birth weight population. , 1995, Pediatrics.

[65]  T. Petty,et al.  Chronic lung disease. , 1989, Postgraduate medicine.

[66]  John Bain,et al.  FOLLOW-UP MANAGEMENT OF THE HIGH RISK INFANT , 1988 .

[67]  H. Taeusch,et al.  Follow Up Management of the High Risk Infant , 1987 .

[68]  J. Tanner Growth failure. , 1981, British medical journal.

[69]  P. Ellison,et al.  Progressive central nervous system deterioration: A complication of advanced chronic lung disease of prematurity , 1980, Annals of neurology.

[70]  L. Papile,et al.  Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. , 1978, The Journal of pediatrics.

[71]  E. Reynolds,et al.  Brain maturation and damage in infants dying from chronic pulmonary insufficiency in the postneonatal period , 1974, Archives of disease in childhood.

[72]  Sattar Alshryda,et al.  Development and Reliability of a System to Classify Gross Motor Function in Children with Cerebral Palsy , 2014 .

[73]  Craig A. Albers,et al.  Third Edition. San Antonio, TX: Harcourt Assessment - Test Review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development , 2014 .

[74]  J. Stockman Intensive Care for Extreme Prematurity — Moving Beyond Gestational Age , 2010 .

[75]  H. Lee Growth and Neurodevelopmental Outcomes After Early Low-Dose Hydrocortisone Treatment in Extremely Low Birth Weight Infants , 2008 .

[76]  A. Fanaroff,et al.  Object working memory deficits predicted by early brain injury and development in the preterm infant , 2007 .

[77]  D. Grier,et al.  Management of bronchopulmonary dysplasia in infants: guidelines for corticosteroid use. , 2005, Drugs.

[78]  L. Monte,et al.  [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.

[79]  R. F. Soil Corticosteroids for the treatment and prevention of chronic lung disease. , 2003, Acta paediatrica.